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SUMMARY 
 
The aim of this study was to evaluate the efficacy of antimicrobial photodynamic therapy (aPDT) 
against a bacterial suspension prepared from three different bacterial species on titanium and 
zirconia dental implants, and to analyze the possible alterations of the implant surfaces as a result 
of aPDT. 
The study was conducted on 72 titanium dental implants and 72 zirconia dental implants 
contaminated with a bacterial suspension prepared from three bacterial species. The contaminated 
implants were randomly divided into four experimental groups and two control groups (n=12 
each), according to the following treatment protocols: Group 1 (PDT1): PDT (660 nm, 100 mW, 
60 seconds) with toluidine blue; Group 2 (PDT2): PDT (660 nm, 100 mW, 60 seconds) with 
phenothiazine chloride dye; Group 3 (PDT3): light emitting diode (LED) with toluidine blue; 
Group 4 (TB): treatment with only toluidine blue for 60 seconds. In the positive control (PC) 
group, the implants were treated with a 0.2% chlorhexidine-based solution for 60 seconds, and in 
the negative control (NC) group no treatment was used. 
In the titanium implants, the highest bacterial reduction was recorded in the PDT1 (98.3%) and 
PDT2 (97.8%) groups. Results of this study showed that there was a statistically significant 
reduction of bacteria in the PDT1 and PDT2 groups compared to the NC group (<0.05), 
individually for each bacterial species, as well as for all three species together. PDT3 was less 
effective than PDT1 and PDT2, and did not show a statistically significant difference compared 
with NC or any other treatment group. TB was the least effective treatment in terms of both the 
total bacterial count and the individual count for each bacterial species. 
In the zirconia implants all the study groups had significantly lower bacterial counts (>99.9%) 
when compared with NC for the total bacterial count and each bacterial species separately. 
Among them the highest bacterial reduction was recorded in PDT1, PDT2 and PDT3, and  all of 
them were also significantly different from TB.  
 PDT1 and PDT2 protocols showed  high efficacy against a three-day old bacterial biofilm on 
titanium dental implants, while PDT1, PDT2 and PDT3 showed high efficacy on zirconia 
implants.  
Keywords: Photodynamic therapy, titanium implants, zirconia implants, antimicrobial efficacy, 
implant surface, laser, LED 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PROŠIRENI SAŢETAK 
 
Svrha rada 
Cilj ove studije bio je procijeniti učinkovitost antimikrobne fotodinamske terapije (aPDT) u 
trodnevnoj bakterijskoj suspenziji pripremljenoj od tri različite bakterijske vrste primijenjene na 
površinu titanskih i cirkonskih dentalnih implantata, te analizirati moguće promjene površina 
implantata kao rezultat djelovanja aPDT-a. 
 
Materijali i postupci 
Istraživanje je provedeno na 72 titanska dentalna implantata i 72 cirkonska dentalna implantata 
kontaminirana bakterijskom suspenzijom pripremljenom od tri bakterijske vrste: Prevotella 
intermedia, Aggregatibacter actinomycetemcomitans i Porphyromonas gingivalis. Kontaminirani 
implantati su inkubirani u anaerobnim uvjetima kroz 72 sata, a potom slučajnim odabirom 
podijeljeni u četiri eksperimentalne skupine i dvije kontrolne skupine (n = 12 po skupini) prema 
sljedećim protokolima tretiranja: Grupa 1 (PDT1): PDT (660 nm, 100 mW, 60 sekundi) s 
toluidinskim modrilom; Grupa 2 (PDT2): PDT (660 nm, 100 mW, 60 sekundi) s fenotiazinskim 
kloridnim bojilom; Grupa 3 (PDT3): svjetleća dioda (LED) s toluidinskim modrilom; Skupina 4 
(TB): tretiranje samo toluidinskim modrilom kroz 60 sekundi. U pozitivnoj kontrolnoj skupini 
(PC) implantati su tretirani s 0,2%-tnom klorheksidin-baziranom otopinom tijekom 60 sekundi, a 
u negativnoj kontrolnoj skupini (NC) nikakav tretman nije korišten. 
 
Rezultati 
U skupini titanskih implantata, najviše redukcije bakterija zabilježeno je u skupinama PDT1 
(98,3%) i PDT2 (97,8%). Rezultati ovog istraživanja pokazali su statistički značajno smanjenje 
bakterija u skupini PDT1 i PDT2 u usporedbi s NC grupom (<0,05), pojedinačno za svaku vrstu 
bakterija, kao i za sve tri vrste zajedno. PDT3 je bio manje učinkovit nego PDT1 i PDT2 i nije 
pokazao statistički značajnu razliku u usporedbi s NC ili bilo kojom drugom skupinom tretiranja. 
TB je bio najmanje učinkovit tretman, s obzirom na ukupni broj bakterija i pojedinačni broj za 
svaku pojedinu vrstu bakterija. 
U skupini cirkonskih implantata sve ispitivane skupine imale su znatno niži broj bakterija (> 
99,9%) u usporedbi s NC za ukupni broj bakterija i svaku bakterijsku vrstu odvojeno. Među 
njima je najveće smanjenje bakterija zabilježeno u slučaju korištenja PDT1, PDT2 i PDT3, od 
kojih su svi bili statistički značajno različiti od TB. 
 
Zaključak 
PDT1 i PDT2 protokoli pokazali su visoku djelotvornost protiv trodnevnog bakterijskog biofilma 
na titanskim dentalnim implantatima, dok su PDT1, PDT2 i PDT3 pokazali veliku učinkovitost 
na površini cirkonskih implantata. 
 
 
Ključne riječi 
fotodinamska terapija, titanski implantati, cirkonski implantati, antimikrobni učinak, površina 
implantata, laser, LED 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The list of abbreviations 
 
Abbreviation Term 
3
O2 Ground state Oxygen 
Al2O3 Aluminium oxide 
ALA 5-aminolevulinic acid 
aPDT Antimicrobial photodynamic therapy 
ATZ Alumina-toughened zirconia 
BOP Bleeding on probing 
BPD Benzoporphyrin derivative 
BRONJ Bisphosphonate-related osteonecrosis of the jaw 
CAL Clinical attachment level 
CFU Colony forming units 
CO2 Carbon dioxide 
CpTi Commercially pure titanium 
Er:YAG  Eribium: yttrium-aluminium-garnet 
GaAlAs Gallium-aluminium-arsenide 
HA Hydroxyapatite coating 
HGF Human gingival fibroblasts 
HiVac High vacuum  
HO:YAG Holmium: yttrium-aluminium-garnet 
HV High voltage  
KTP Potassium titanyl phosphate 
LED Light-emitting diode 
LLLT Low level laser therapy 
LS11 Talaporfin sodium 
LTD Low temperature degradation 
MRONJ Medication-related osteonecrosis of jaws   
mTHPC Temoporfin 
MVD Microvessel density 
NaOCl Sodium hypochlorite 
ND:YAG Neodymium:yttrium-aluminium-garnet 
NOS Nitrous oxide synthase 
PDT Photodynamic therapy 
ROS Reactive Oxygen Species 
SCC Squamous cell carcinoma 
SEM Scanning electron microscopy 
SnET2 Tinethyletiopurpurin 
Ti Titanium 
TPS Titanium plasma-sprayed 
UV Ultraviolet 
VEGF Vascular endothelial growth factor 
Y-TZP Yttria tetragona zirconia polycristalline 
ZTA Zirconia-toughened alumina 
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Dental implants are becoming a routine procedure in modern dentistry. They  can potentially  last 
a patient’s entire life.  The increase in the number of dental implants placed every year has also 
been accompanied with an increase in the number of peri-implant diseases. Peri-implantitis is a 
serious complication that can lead to the disintegration and early loss of the implants. Currently 
there are no standardized treatment protocols for treating peri-implant diseases. This gives rise to 
many new challenges in finding a successful treatment method and establishing an effective 
treatment protocol. Photodynamic therapy has recently emerged as a potential effective treatment 
choice for peri-implantitis due to its non-invasiveness and good antimicrobial effects.  
 
1.1 Photodynamic Therapy 
1.1.1 Historic overview 
 
The first use of light for therapeutic purposes dates from around 1400 BC when the sunlight was 
used as a source for treating skin diseases (1).  
In 1801  ultraviolet (UV) rays were discovered and scientists began to  understand the therapeutic 
effect of the sunlight. Later during the 19
th
 century the interest for heliotherapy increased in the 
scientific community and different scientists started using the sunlight to treat different diseases 
such as rachitis, peritoneal tuberculosis, lupus vulgaris, etc. (1). 
Towards the end of the 19
th
 century, Lahmann constructed and used the first artificial light 
sources in Germany. His construction was made from a carbon arc lamp in combination with a 
parabolic mirror. He successfully treated a patient with lupus vulgaris of the nose and recorded an 
improvement in another patient that had the same condition (2). 
In the beginning of the 20
th
 century, Niels Finsen received the Nobel Prize for his therapeutic 
results in treating lupus vulgaris with concentrated doses of UV radiation from a carbon arc lamp. 
This was regarded as the beginning of  modern phototherapy (1). 
In the mid of the 20
th
 century scientists and doctors started using artificial light sources for 
treating neonatal jaundice, psoriasis, and many different skin conditions (3). 
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Nowadays this technology is known as phototherapy. Phototherapy can be used with or without 
the use of a photosensitizer. When used together with a photosensitizer, phototherapy is known as 
photochemotherapy (2). 
Photodynamic therapy (PDT) is a type of photochemotherapy which involves three components: 
light, a photosensitizer and oxygen. The therapeutic possibilities of photodynamic therapy were 
first introduced in the 19
th
 century, but  it was not until the 1990s when the first photosensitizers 
were approved for clinical use (2,4,5). 
Currently photodynamic therapy is mostly used in the treatment of cancers (6–8), however, there 
are numerous recent studies that have shown that photodynamic therapy also has antimicrobial 
effect (9–12).  
 
1.1.2 Photochemistry of  Photodynamic Therapy 
 
Photodynamic therapy (PDT) is a treatment  in which a photosensitive dye (photosensitizer) is 
activated by light, which leads to selective toxicity for the desired treatment (13). 
As a result of the light activation, the sensitizer is transformed from ground state to the first 
excited state. In this state the photosensitizer has to have enough stability so that it can cross to 
the triplet excited state (T1), which is an even more stable state. Subsequently two different 
reaction processes, both involving molecular oxygen, can take place. In the first type (Type I), the 
Reactive Oxygen Species (ROS) are formed as a result of the interaction of ground state oxygen 
with the resultant radical which is created from the hydrogen abstraction or electron transfer 
between an excited sensitizer and an adjacent sensitizer molecule. In the second type (Type II), 
singlet oxygen species are formed as a result of the energy transfer directly from T1 to the ground 
state oxygen (
3
O2). This can happen only if the sensitizer and the ground state oxygen are in the 
same triplet state multiplicity (2,13). Both types of processes are shown schematically in Figure 
1. 
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Figure 1. Photochemical mechanisms in photodynamic therapy (Type I and Type II). 
 
The Type I reaction mainly happens in anoxic or hypoxic environments. In anoxic environments 
the excited photosensitizer reacts directly with organic substrates, producing an oxidized 
substrate and a reduced photosensitizer. In hypoxic environments the reduced photosensitizer 
reacts with oxygen and superoxide anions are produced which,  as a result,  can form highly 
reactive hydroxyl radicals (4).  
Type II reactions are dependent on oxygen concentration. They are commonly associated with the 
formation of singlet oxygen, however, there are also other compounds which have triplet-ground 
state similar to oxygen which can be involved in this type of reaction (nitric oxide and vitamin A) 
(4, 14). Type II reactions are  dominant  during PDT treatments, however Type I reactions might 
become dominant under hypoxic conditions or in the presence of highly concentrated 
photosensitizer (2, 4).  
 
1.1.3 Oxygen in Photodynamic Therapy 
 
Oxygen is one of the three components of photodynamic therapy. In its ground state, oxygen has 
two unpaired electrons that are positioned on the outermost orbitals.  Depending on the presence 
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or absence of magnetic field, these electrons can have three different configurations: both spins 
aligned up, both spins aligned down or in opposite directions. Because of these three possible 
configurations, the ground state of oxygen is also called a triplet state (4).  
The predominant agent produced from photodynamic therapy is the singlet oxygen (2). This is a 
highly reactive form that happens as a result of pairing electrons into antibonding orbital which 
makes the molecule unstable. The lifetime of singlet oxygen is very short due to its reactiveness, 
and as a result of this short lifetime the energy created and the oxidative damage induced by PDT 
is highly localized (2,4) (Figure 2). 
 
Figure 2. States of oxygen. Triplet (
3
O2) and singlet (
1
O2) oxygen (2). 
 
1.1.4 Photosensitizers in Photodynamic Therapy 
 
The first photosensitizers used for photodynamic therapy were porphyrins, chlorins and 
bacteriochlorins. These dyes have the strongest light absorption in the red portion of the 
electromagnetic spectrum. Among them there are differences in the absorption spectra ranging 
from around 400 nm (called the Soret band) to around 800 nm, however, the most useful 
absorption range for PDT is between 600 nm and 800 nm. These photosensitizers are highly 
efficient singlet oxygen generators. The production efficiency of singlet oxygen is called singlet-
oxygen quantum yield (Φ) (2,4,5). 
An optimal photosensitizer should have the following properties (15): 
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1. availability in pure form 
2. it should be synthesizable and easily reproduced 
3. high singlet-oxygen quantum yield  
4. strong absorption in the spectrum (680-800 nm) 
5. effective accumulation in tumor tissue 
6. stability and solubility in the organism 
7. excretion from the body after completing the treatment. 
 
The first commercial photosensitizer was Photofrin
®
. It belongs to porphyrin group of 
photosensitizers. Its longest wavelength absorption maximum is relatively weak. At 630 nm it 
can be activated up to about 5 mm in the tissues. At the beginning it was approved only for 
treating bladder cancer, but later it was also approved for treating many other cancers 
(esophageal, lung, head, neck, abdominal cancer etc.) (4,5,15). 
In an attempt to create a better photosensitizer, many new compounds have been synthesized. The 
second generation of photosensitizers includes 5-aminolevulinic acid (ALA), benzoporphyrin 
derivative (BPD), lutetium texaphyrin, temoporfin (mTHPC), tinethyletiopurpurin (SnET2), 
talaporfin sodium (LS11), etc. These compounds are more potent than the first generation and 
due to their potency they can cause pain and lead to severe skin photosensitivity. The third 
generation of photosensitizers includes modified drugs that are currently available, but more 
studies are needed to verify the potential of these photosensitizers (2,4,5,15).  
Even though most of the photosensitizers belong to the porphynoid groups, there are also several 
non-porphyrin photosensitizers. These compounds include: antharquinones, phenothiazines, 
xanthenes, cyanines etc. (2). 
In dental medicine  most commonly used photosensitizers belong to the phenothiazines. 
Methylene blue and toluidine blue are the most commonly used to treat chronic periodontitis. 
Methylene blue  is used in addition against melanoma, basal cell carcinoma and Kaposi’s 
sarcoma (13,16). The structures of methylene blue and toluidine blue are presented in Figure 3.  
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Figure 3. Structure of Methylene blue and Toluidine blue (2). 
Methylene blue and toluidine blue belong to the phenothiazinium family with similar chemical 
and physicochemical characteristics. Methylene blue is a redox indicator which is blue in an 
oxidizing environment  and upon reduction becomes colourless (16). At first it was used as a 
medicine against malaria (17). The best absorption of methylene blue occurs at the wavelength of 
666 nm (2). Its mechanism of action is due to its positive charge and it includes the interleaving 
of methylene blue cations in the structure of nucleic acids. A disadvantage of methylene blue is 
the fact that this chromophore is easily reduced in biological systems, which as a results reduces 
the antimicrobial activity (18). However, many studies report methylene blue to be effective in 
killing Helicobacter pylori, Candida albicans,  the influenza virus and periodontal bacteria (19–
22). 
Toluidine blue has a blue-violet colour. It is capable of inactivating gram-positive and gram-
negative bacteria. It interacts with lipopolysaccharides that are present in the cell membrane of 
Gram-negative bacteria even without light application (16,23,24). When exposed to a wavelength 
of 630 nm,  it shows maximum absorption and is effective in killing various types of 
microorganisms (13,16). Its mechanism of action is due to its chemical and physical properties 
that allow it to pass freely across the bacterial membrane and act directly on the mitochondria 
(18). It has been shown in different studies that toluidine blue is effective against periodontal 
bacteria both in planktonic cultures (25,26) and biofilms (22). 
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1.1.5 Light Sources 
 
The first light sources used for PDT were argon-pumped dye lasers, potassium titanyl phosphate 
(KTP)- or neodymium:yttrium aluminium garnet (Nd:YAG)-pumped dye lasers, and gold vapor- 
or copper vapor-pumped dye lasers. All these devices are expensive and complex, which is why 
nowadays  diode laser systems are predominantly used. Diode lasers  are easy to handle, portable 
and less expensive compared to previously used devices (5,27). 
For an effective PDT treatment, the light source should be capable of activating the 
photosensitizer at a specific wavelength. Red light is the most efficient one regarding the use in 
human tissues. As a result, most of the sensitizers used are between 630 and 700 nm. This 
corresponds to a light penetration depth of up to 1.5 cm (27,28). This limited depth of penetration 
prohibits the uniform illumination of larger and solid tumors (7,29).   
Recently, non-laser light sources, such as light-emitting diodes (LED), have also been applied in 
PDT procedures. These light sources are much less expensive and are small, lightweight, and 
highly flexible (9,30–32).  
The PDT, depending on the pathology treated, can be applied superficially, interstitially, intra-
operatively, and intra-cavitary.  
Depending on the location and morphology of the lesion, sources used for light delivery can be 
fiber-optic catheters or lenses for flat-field applications (7,29).  
The light should be precise and uniform allowing for an effective treatment. The fiber tip can 
have different shapes in order to allow light diffusion in all directions. Important issues related to 
the light source for PDT are the accurate calibration, sensitizer and light dosimetry. Such devices 
would greatly advance PDT as a routine clinical treatment (33). 
 
1.1.6 Limitations of Photodynamic Therapy 
 
In order for PDT to be effective it requires the light to be directed to the appropriate site and 
tissue depth. Optimal light delivery with lasers and the coordination between different clinicians 
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is complex and sometimes the availability of the light sources is a major issue. Currently there are 
portable light sources which have simplified the process. PDT is an ablative procedure and the 
treatments do not provide material for histopathological diagnosis. That is why prior to the 
application of PDT, a treatment diagnosis should be made by other methods. Another limitation 
of PDT is the inability of the light to penetrate deep in tumors which makes it less effective for 
treating large tumors. Since it is a local treatment, it is also impossible to be used for treating 
metastasized cancers (34–36). 
Photosensitivity is another issue that can last for some time after the application of certain 
photosensitizers. It is dependent on the method of application of the photosensitizer. When 
administered systematically, skin photosensitivity may last for  several days or weeks. Patients 
are instructed to avoid exposure to sunlight, protect the skin and the eyes until the drug is 
completely eliminated (5).  
 
1.1.7 Antimicrobial Photodynamic Therapy (aPDT) 
 
The antimicrobial potential of PDT has been known since the beginning of the last century. 
However, it was not until  the emergence of antibiotic-resistant strains of bacteria that  scientists 
were stimulated to look for alternative treatments, especially for localized infections of the skin 
and oral cavity (5,37,38). 
The products of photodynamic therapy cause damage to various components of the microbial 
cells or they can alter the metabolic activity irreversibly. This results in microbial elimination. 
This mechanism of action is based on the energy absorbed through intracellular 
photosensitization which is transferred to the oxygen molecule in order to damage the oxidative 
reaction pathways in the plasma membrane and the genetic material of the microbial cells 
(39,40). This effect is limited only on the microbial cells without any toxic effects for the host 
cells (41).  
The efficiency and reliability of aPDT is due to the relatively simple basic principles behind it. If 
all the components of aPDT (light, oxygen and photosensitizer) are present in sufficient amounts 
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during the application of this therapy, then this technique can be highly effective and cause 
damage to the target cells (42).  
The antimicrobial effect of photodynamic therapy has been shown to be effective in many studies 
and against a number of different microorganisms: Agerggatibacter actinomycetemcomitans, 
Prevotella intermedia, Staphyloccocus aureus. Streptococcus pneumoniae, Enterococcus faecalis, 
Escherichia coli, Candida albicans, Pseudomonas aeruginosa, Porphyromonas gingivalis, 
Streptococcus sanguis etc. (9,18,23,30,43). It is unlikely that these microorganisms can develop 
resistance to aPDT. This is due to the fact that singlet oxygen and the free radicals interact with 
several cell structures and different metabolic pathways in the cellular level (44). 
 
 
1.2 Application of Photodynamic therapy in dental medicine 
 
The application of PDT in dental medicine is growing rapidly and it is being used for the  
photodynamic diagnosis of malignant transformation of oral lesions, the treatment of head and 
neck cancer, as well as bacterial and fungal infections (5,45). 
 
1.2.1 Application in Periodontology 
 
Periodontitis is a chronic inflammatory disease affecting tissues surrounding the teeth. It is 
induced by bacterial infection and causes major destruction of the periodontium which can 
eventually  lead to the loosening of the teeth and their subsequent loss (46,47).  
The basic treatment of periodontitis consists of the mechanical debridement, often combined with 
the use of chemical decontamination or the use of systemic or local antimicrobial therapy.  
The mechanical debridement alone cannot remove all the infections due to the difficulty in 
reaching deep pockets and as a result, a residual plaque can remain even after the treatment. 
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When mechanical debridement is repeatedly used, it can lead to cumulative scuffing of the root 
surface (48). 
The systemic delivery of antimicrobial therapy has some side effects, including antibiotic 
resistance which should  always be considered when treating periodontitis. The local application 
of the antimicrobial therapy also has some disadvantages, such as the necessity to repeat the 
treatments, the effect appears only in a limited part of the periodontium and decalcification and 
root surface softening can occur (49–51). Furthermore, mechanical debridement can open 
dentinal tubes and the remaining periodontal bacteria are able to penetrate into the dentinal tubes 
(13,52,53). 
The limitations of the traditional periodontal therapy have shifted the focus towards aPDT as an 
alternative treatment for periodontal diseases (54–56). It has been confirmed  in many studies that 
aPDT is an effective antimicrobial therapy (12,36).  
The advantages of aPDT in comparison with other treatments are that the photosensitizer can be 
placed directly into the pocket and then activated with an optical fiber tip.  Another advantage is 
that aPDT is effective only against microbial cells, avoiding damage to the host tissues. This 
makes it a safe procedure against periodontal microbiota (57,58).  
Many studies have shown  potential improvements after the use of aPDT in conjunction with 
mechanical debridement (59–61), however there are also some studies that report different results 
(55,62–64).   In his meta-analysis Atieh (61) showed potential improvements after using aPDT 
together with scaling and root planning. A reduction in probing depth and greater clinical 
attachment gain was seen in association with those two treatments. Similarly, in their study  
Sgolastra et al.  reported that the combination of aPDT and conventional treatment provides 
additional benefits by reducing the pocket depth and increasing the clinical attachment level 
(CAL) (59). 
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1.2.2 Application in Oral and Maxillofacial surgery 
 
In the oral and maxillofacial region, photodynamic therapy is used for its anti-cancer therapeutic 
potential and for its antimicrobial potential. The main focuses of the anti-cancer photodynamic 
therapy in this region are head and neck cancers.  Most of the head and neck cancers are 
squamous cell carcinomas (SCC). Oral SCC is the most frequent tumor in the oral cavity (65). 
Conventional methods used for treating head and neck cancer have not shown any significant 
improvements in the 5-year survival rate of these cancers. They also cause different side effects 
such as jaw pain, mouth sores, difficulty in chewing, swallowing, etc. (66). 
Pre-malignant lesions of the oral mucosa are considered as one of the developing factors of oral 
SCC. Erythroplakias and dysplastic leukoplakias are the most common pre-cancerous lesions. 
Around  50% of oral SCC are associated with leukoplakias (67). 
Photodynamic therapy has therapeutic potential not only for the head and neck cancer, but also 
against  pre-malignant, primary, recurrent, and metastatic lesions (68,69).  
Compared to conventional treatments, PDT has an advantage due to its minimal invasiveness and 
selective tumor destruction without affecting the healthy tissues.  In addition, it can be applied in 
combination with conventional therapy to increase the overall treatment success (29).  The mostly 
used and studied photosensitizer is Photofrin
®
, but it has limited application for treatment of large 
and solid tumors. The clinical results obtained from the use of  Photofrin
®
 for head and neck 
cancer are generally excellent (70). A major side-effect after Photofrin
®
 use is the 
photosensitivity of the skin which can last for up to 6 weeks after treatment (29,70). 
Focsan
®
 is a second-generation photosensitizer, the aims of which include: local destruction of 
the tumor, preservation of organ function, relief of symptoms and avoiding disease-related 
complications. Similarly to other photosensitizers, it causes photosensitivity after treatment. This 
can last for approximately 15 days  (70). 
A newer generation of photosensitizer is ALA, which is a precursor of the photosensitizer 
protoporphyrin IX. It is mostly used for superficial lesions due to its limited depth and light 
penetration. The photosensitivity after treatment lasts less than 24 hours. This photosensitizer has 
been widely used in the treatment of pre-malignant lesions in the oral cavity (27,71–73). 
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Regarding the antimicrobial effect of PDT in oral and maxillofacial surgery, it is mostly used for 
the disinfection of soft tissue or bone during final surgical phases as an additional means of 
prevention.  In their study Neugebauer et al. (74)  showed that after the use of aPDT there is a 
significantly lower incidence of alveolar ostitis. Nagayoshi et al. (75) concluded that 
photodynamic therapy had nearly the same antimicrobial effect as 2.5% NaOCl without adverse 
effects on surrounding tissues. Their study was conducted on in vitro periapical lesion model.  
Photodynamic therapy has recently  also been used as an adjuvant therapy for the treatment of 
medication-related osteonecrosis of jaws (MRONJ), which is highly related to bisphosphonate-
related osteonecrosis of the jaw (BRONJ). Minamisako et al. (76), according to their results, 
suggest that both LLLT (low level laser therapy) and PDT are beneficial in the treatment and  
clinical management of the MRONJ. Similarly, Rugani et al. (77) in their review conclude that 
photodynamic therapy can be used as an adjunct therapy in BRONJ treatment before or after 
surgery. It can also be used as a primary treatment option in cases of very early BRONJ or if 
surgery is not indicated. 
 
1.2.3 Application in Endodontics 
 
In endodontics aPDT is used for the disinfection of the root canal. Conventional root canal 
treatment consists of a combination of mechanical instrumentation, the use of disinfecting 
solutions for irrigation and the placement of medicaments in between appointments. However, 
due to the root canal anatomy, sometimes the complete disinfection of the root canal is very 
difficult while using mechanical and chemical methods (78,79). 
 In an in vitro study by Bago et al. (80), the antimicrobial efficacy of photodynamic therapy  was 
shown to be more effective in reducing root canal infection compared to  high-power diode laser 
and conventional irrigation with NaOCl (sodium hypochlorite).  
The use of aPDT has also been shown effective as an adjunct therapy for the root canal 
disinfection in many studies. Raymond at al. (78) in their in vitro study tested the efficacy of 
conventional chemo-mechanical treatment together with photodynamic therapy. Their results 
showed that this combination is more effective than the use of only chemo-mechanical treatment. 
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Rios et al. (81) in their study used a light-emitting diode in combination with toluidine blue O. 
They concluded that photodynamic therapy has the potential to be used as an adjunctive 
antimicrobial procedure in endodontics. Similarly, Bago et al. (82) in their clinical study 
concluded that the of the effect of aPDT,  in addition to the conventional chemo-mechanical root 
canal preparation, led to a significant reduction of the bacteria and in some samples the complete 
elimination of bacteria. 
 
 
1.3 Dental Implants  
 
Per-Ingvar Brånemark in 1978 presented two-stage threaded implants made from titanium in a 
root-form. With his research that started in 1965 he established the basis for modern 
implantology. The first four implants placed by Brånemark in 1965 integrated within six months 
and remained in place for over 40 years (83). 
The concept of osseointegration of the implants was first brought during the 1950s and 1960s 
after observing in many studies that there was a bone growth in contact with titanium in many 
animal studies. Brånemark defined osseointegration as: “A direct connection between living bone 
and a load-carrying endosseous implant at the light microscopic level.” (84). 
Since then dental implants have become a long-term reliable treatment option for replacing 
missing teeth (85). An ideal implant should have the following properties: biocompatibility, 
adequate toughness, strength, corrosion resistance, facture and wear resistance (86,87). Materials 
for producing dental implants can be categorized according to the biological response or the 
chemical composition. Regarding their chemical composition,  they can be produced from metals, 
ceramics or polymers (88). 
Up to date, titanium implants and their biomedical alloys are the ―gold standard‖ for producing 
dental implants. This is due to the excellent biocompatibility and long-term survival rate of 
titanium implants (89–91). However, there are some concerns regarding their dark gray colour, 
which can be visible through the peri-implant soft tissue, especially when a thin biotype of 
gingiva is present, or when a resorption of the buccal plate occurs (90,92). Furthermore, titanium 
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dental implants might cause galvanic side effects after contact with saliva, and even though they 
are rare, allergic reactions might be possible (93,94). Due to these reasons, many scientists have 
shifted their focus to producing ceramic implants (95). 
 
1.3.1 Titanium Dental implants 
 
There are six types of titanium available as implant material. They are classified by the American 
Society for Testing and Materials into four grades of commercially pure titanium (CpTi) and two 
titanium (Ti) alloys (85,96). 
CpTi has mechanical and physical properties different from the two titanium alloys, mainly due 
to the oxygen residuals in the metal. They are classified from Grade I to Grade IV pure titanium. 
In CpTi there are usually some trace elements, such as carbon, oxygen, nitrogen and iron, which 
improve the mechanical properties of pure titanium. Their amount increases with the increasing 
grade from I to IV (85,96). 
The titanium alloys used in dentistry have three structural forms depending on the elements 
mixed with titanium: alpha (α), beta (β) and alpha-beta. These structural forms can coexist 
depending on the composition and the heat treatment of  titanium (86,97). The most commonly 
used structural form for the production of dental implants is the alpha-beta combination. This is 
known as Ti-6Al-4V and contains 6% aluminium and 4% vanadium. These alloys have low 
density and are strong and resistant to corrosion and fatigue (85). They have a module of 
elasticity similar to bone, which enables a more favorable stress distribution at the bone-implant 
interface (96). 
In addition to enhancing the titanium properties, many modifications to the implant surface have 
been made with the purpose of decreasing the healing time for osseointegration. The only part 
that is in contact with the bioenvironment is the surface of the dental implant and it is this 
interaction that affects the implant/tissue interface (83,98). 
Surface treatment of the dental implants increases the functional surface area of the implant-bone 
interface and stress is more effectively transferred. There are also surface treatments that promote 
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bone apposition. The most common treatments include mechanical treatments, chemical 
treatments, electrochemical treatments, thermal treatments and laser treatments (99,100). 
Increasing the surface roughness of the implant has been shown to influence the production of 
cytokine and growth factors by osteoblasts. It also increases osteoblast cell propagation by 
transforming growth factors (101). This suggests that the implant structure directly influences the 
interaction between the metal and the surrounding living tissue (102,103). 
The first implants that were produced after Brånemark introduced the concept of osseointegration 
were the ones with smooth machined surface, and they were also called  machined implants. 
These implants required a longer osseointegration period due to their smooth surface, but in 
accordance with Brånemark’s two stage concept. These implants show good long-term results 
when they are used in the areas with sufficient bone, allowing for a two-stage process 
(83,104,105). 
Later ceramics were introduced  in dental implantology for coating endosseous implants in order 
to improve osseointegration (106).  Calcium phosphates, bioglasses, inert ceramics and zirconium 
oxide have been used for this purpose. The thickness of the coating varies from 1 to 100 μm, 
depending on the coating method. The coating can be done using plasma spraying, sputter-
deposition, sol-gel coating, electrophoretic deposition or biomimetic precipitation (106,107). In 
many studies bioactive ceramics have been shown to enhance bone apposition as compared with 
inert ceramics and metallic surfaces. This is due to the release of calcium phosphate ions around 
the implants (106–109). The most popular calcium phosphate coating materials today are 
hydroxyapatite and fluorapatite.  
Hydroxyapatite coating (HA) is a surface treatment  of titanium dental implants in order to form a 
stronger bond between the bone and the implant (110).  The HA is mostly applied to the titanium 
surface by plasma spraying which allows a uniform thickness of 40-50 micrometers (111). 
A major concern regarding the plasma spraying is that  hydroxyapatite may resorb eventually, 
which might ultimately cause loosening of the titanium particles. Another concern regarding this 
method is the implant failure due to microbial infection (112–115).  
Another surface treatment is the etching of the implant surface with strong acids like hydrochloric 
or sulfuric acid. This procedure provides an equal roughness, active surface area and better 
adhesion (116). It also eliminates the oxide layer from the implant surface (117).  Acid etching 
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has improved the osseointegration according to Cho et al. (118)  and Wong et al. (119) in their 
respective studies.  
In addition to these methods, some manufacturers use fluoride treatment, or laser ablation for the 
implant surface (83,120). The use of antibiotics has also been studied on the implant surface in 
order to prevent the infection of the surgical site. For this purpose, tetracycline has shown good 
results and it supports osseointegration of the implant (121,122). 
Recently, titanium implant coatings with antimicrobial properties are being evaluated in many 
studies (123,124).  Kulkarni Aranya et al. (124) investigated different modifications of calcium 
phosphate coatings on titanium discs. According to their results, the growth, colonization and 
adherence of P.gingivalis were inhibited.  
 
1.3.2 Zirconia Dental Implants 
 
As an alternative to titanium dental implants, recently novel implant technologies that produce 
ceramic implants have been introduced (95). 
Initially ceramic implants were made from mono or polycrystalline aluminium oxide (Al2O3), 
however due to its mechanical weakness it resulted in poor clinical outcome (125).  
Nowadays, ceramic dental implants are produced from yttria stabilized tetragonal zirconia 
polycrystalline (Y-TZP) (126). Compared to other ceramics, zirconia holds a unique place due to 
its excellent mechanical properties and it exhibits superior corrosion and wear resistance. It also 
has a high flexural strength compared to other dental ceramics (126,127). This makes them 
suitable substrates for the production of dental implants (125). 
In preclinical studies the biological and physical properties of Y-TZP implants have been shown 
to be comparable to titanium implants (128–131). 
Recently several clinical studies have addressed the outcome of implants produced from Y-TZP. 
Promising results have been found in a recent review regarding the survival rate and the marginal 
bone loss after one year in function (132). However, long-term clinical results are still missing. 
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The main concern regarding zirconia as implant material is low temperature degradation (LTD). 
This process is also known as ageing and it occurs by a slow surface transformation of the 
tetragonal crystals to stable monoclinic structure when water or water vapor is present. To a 
certain degree this transformation improves the mechanical properties of Y-TZP, however 
between the improvement and destruction there is a narrow range which seldom results in 
property deterioration of the material (133).  In order to minimize LTD, many manufacturers 
have included the addition of small amounts of silica,  reduced the grain size, increased the 
stabilizer content,  used yttria-coated powder instead of co-precipitated powder, or even formed 
composites with aluminium oxide (134–136). The addition of alumina to zirconia stops the 
ageing or at least reduces its kinetics drastically. This is  a result of the changes in the grain-
boundary chemistry and the limitation to the tetragonal grain growth during sintering. The 
outcome of this is a more stable structure of the material (135). 
In order that an optimal zirconia implant design can be developed, biomechanical failure modes 
of the zirconia should be understood (137). The physical mechanism of ceramic implant failure 
can be mechanical and/or chemical (138). Mechanical failure can occur during the placement of 
the implant or after loading the implant (137,139). 
The manufacturing process of zirconia implants is more complicated and imperfections or flaws 
during the production can compromise their strength (107,137).  There are many manufacturers 
of zirconia implants available today, however only three types are being used in dentistry: 
yttrium-stabilized tetragonal zirconia polycrystals (Y-TZP), alumina-toughened zirconia (ATZ) 
and zirconia-toughened alumina (ZTA) (107). 
Altogether, zirconia implants are becoming an alternative to titanium implants. They have tooth-
like colour, high strength and higher fracture toughness compared to other ceramics (90,126,140). 
According to some studies, zirconia implants induce smaller inflammatory response and bone 
resorption compared with the titanium particles, which suggests good biocompatibility 
comparable to titanium implants (92,141). 
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1.3.3 Peri-implant tissues around zirconia and titanium implants 
 
The soft tissues around the implant form a crucial seal between the implant surface, the bone and 
the oral environment (142,143). In contrast to teeth,  there is no supracrestal connective tissue 
attachment around the implants. This makes the seal fragile and when subjected to bacterial or 
mechanical challenge, the  destruction of the soft connective tissue around the implant can be 
faster and more devastating process compared to the periodontium of the teeth (144,145).  
The inflammatory response of the soft tissues around the implant and the plaques adhesion on the 
implant surface has been studied in many in vitro and in vivo studies. Scarano et al. (146) in their 
study evaluated the coverage of titanium and zirconia discs by bacteria and found that there is a 
significant difference in bacterial adhesion between these types of surfaces. In another study the 
expression of the vascular endothelial growth factor (VEGF), nitrous oxide synthase (NOS) and 
microvessel density (MVD) in titanium and zirconia healing caps was examined. They found out 
that all of these had higher values and greater extension of inflammatory infiltrate in the titanium 
specimens (147). 
Kohal et al. (130) in their study in a monkey model, found no difference in soft tissue integration 
around rough zirconia and  titanium implants. In another study the attachment, growth behavior 
and the effect of human gingival fibroblasts (HGF) cultured on zirconia and titanium surfaces 
was investigated. In  this study the biological response to zirconia and titanium were comparable 
(148). 
Consequently, enhancing the seal formed by the peri-implant soft tissues, especially that of the 
titanium/connective tissue interface may be an important factor in implant survival. 
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1.4 Peri-implantitis and aPDT 
 
Peri-implant diseases can be presented in two forms: peri-implant mucositis and peri-implantitis. 
Peri-implant mucositis is the reversible inflammatory process of the soft tissue around the 
implant, which is followed by reddening, swelling and bleeding on probing (149). 
Peri-implantitis is an inflammatory process affecting the soft and hard tissue around an 
osseointegrated implant, resulting in the loss of supporting bone (150). 
The literature provides widespread evidence of the microbial etiology of peri-implantitis (151). 
The microorganisms found in peri-implantits are very similar to those found in advanced 
periodontitis (152–154).  Most of them are spirochetes and non-motile anaerobic Gram-negative 
bacteria such as: Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis, Prevotella 
intermedia, Tannarella forsythia, Treponema denticola etc. (155,156). 
The colonization of the implant surfaces with bacterial biofilms occurs rapidly in the oral cavity. 
In the early stages of peri-implantitis there are no significant symptoms, hence it is usually 
diagnosed during routine dental check-up. The early diagnosis of peri-implantitis is of great 
importance in order to stop the progression of the disease and to establish good osseointegration 
(157–159).  
According to Teughels et al. (160), in addition to the chemical composition, the surface 
roughness of the implan has a significant impact on the quantity and quality of plaque formation 
and bacterial adhesion on implant surfaces.. Rough surfaces and those with greater surface free 
energy accumulate more plaque. Furthermore, the areas with high wettability and pits and 
grooves in the roughened surfaces also attract initial bacterial adhesion which  is difficult to 
remove.  
There are many treatment modalities proposed in literature for treating peri-implantitis. They can 
be summarized in two groups: resective and regenerative therapies (161). 
Resective treatments attempt to eliminate the etiologic factors of peri-implantitis and maintain 
optimal conditions. These treatments are mainly done by cleaning and decontaminating implant 
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surfaces. Regenerative treatments consist in using bone grafts, membranes and growth factors in 
order to reconstruct the pre-existing  hard and soft tissues around the implants (161,162).  
Similarly to treating periodontitis, resective treatments are mainly done by mechanical removal of 
biofilm from the surface of the implant, which is of utmost importance when treating peri-
implantitis.  For this purpose plastic curettes, ultrasonic scalers, air-powder abrasive and ablative 
lasers are used (163). The objective is to create a clean surface which can stop the progression of 
the disease and  promote re-osseointegration of the implant. However, the implant surface 
roughness facilitates bacterial adhesion and colonization which makes mechanical debridement 
very difficult (164).  
Some authors suggest elimination of the implant threads and smoothing the implant surface 
(implantoplasty) in order to achieve better decontamination. This procedure allows better 
maintenance and facilitates the oral hygiene when threads are exposed (165,166).  
The use of plastic curettes is recommended over the use of metallic curettes because metallic 
curettes can alter surface roughness favoring bacterial colonization, whereas plastic curettes 
produce very little damage or none at all. When metallic curettes are used, titanium curettes are 
preferred over stainless steel curettes (167). Abrasive sandblasting systems are also reported  to 
be effective for mechanical cleaning of the implant without producing adverse effects (168).  
Laser decontamination of the implant surfaces has been widely studied recently. In their study 
Kreisler et al. (169) evaluated the mechanical effects produced by Nd:YAG, Ho:YAG 
(holmium:yttrium-aluminium-garnet), Er:YAG (Eribium: yttrium-aluminium-garnet), CO2 
(Carbon dioxide) and GaAlAs (Gallium-aluminium-arsenide) lasers on four types of implant 
surfaces. Their results showed that Nd:YAG and Ho:YAG lasers cause significant damage to the 
implant surfaces. On the other hand, CO2 and Er:YAG lasers can be used in specific power 
settings and GaAlAs laser did not cause any damage to the surface in any power settings.  
In addition to mechanical methods of treating peri-implantitis, the use of chemical 
decontamination and antibiotic therapy is promoted as adjunct therapy to mechanical 
decontamination in order to improve the treatment outcome. The most commonly used 
antimicrobial solutions are chlorhexidine, tetracycline or minocycline, citric acid, hydrogen 
peroxide, and phosphoric acid (170). 
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Recently aPDT has emerged as a potential treatment option or adjuvant treatment to peri-
implantitis. It has generated much interest for its potential to decontaminate implant surfaces 
without damaging the surface and the surrounding tissues around the implant. Furthermore, it is 
more effective than the application of laser alone (164,171).   
In their study Hayek et al. (172)  concluded that aPDT is effective and non-invasive method 
compared to conventional therapy during surgical treatment of peri-implantitis with elevated 
mucoperiosteal mucosa flaps. 
The possibilities of aPDT for treating peri-implantitis are opening new challenges ahead in 
establishing optimal conditions for the clinical application of aPDT. It holds a promise as a novel 
and non-invasive method that can be effective when applied alone or as adjunct therapy to 
conventional methods for treating peri-implantitis (45).  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. The aim and the hypotheses 
 
Bleron Azizi   Dissertation 
 
24 
 
2.1 The aim of the study 
 
The aim of this research is to test and compare the effectiveness of antimicrobial photodynamic 
therapy (aPDT) using three different devices on titanium dental implants and zirconia dental 
implants contaminated with anaerobic and facultative anaerobic bacteria. 
In addition, our aim was to evaluate if aPDT causes damage and alteration to the implant surfaces 
which would interfere with the re-osseoinegration of the implants in clinical conditions.  
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2.2 The hypotheses 
 
1. There is no difference in the treatment outcomes between the study groups and the control 
groups. 
 
2. The effect of the photodynamic therapy is not dependent on the device and 
photosensitizing dye used. 
 
3. The treatment outcome is not affected by the implant material/surface. 
 
4. There are no surface alterations after the use of aPDT 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. Materials and Methods 
 
Bleron Azizi   Dissertation 
 
27 
 
 
3.1 Study sample 
 
The study sample consisted of 144 sterile dental implants out of which 72 were titanium dental 
implants (BlueSky, Bredent
®
, Senden, Germany) and 72 zirconia dental implants (whiteSKY, 
Bredent
®
, Senden, Germany). The approval for the study was obtained from the Ethics 
Committee of the School of Dental Medicine, University of Zagreb (05-PA-26-4/2016). 
 
3.1.1 Titanium Dental Implants 
 
The titanium dental implants used were with a diameter of 4.0 mm and 12 mm of length (Figure 
4). The implants used were with sandblasted and acid etched surface. Each of the implants was in 
an unopened sterile packaging.  
 
 
Figure 4. Titanium dental implant, BlueSky, Bredent
®
, 4.0x12mm 
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3.1.2 Zirconia Dental Implants 
 
The zirconia dental implants used were with a diameter of 4.0mm and 12 mm of length (Figure 
5). The implants used were with sandblasted surface. Each of the implants was in an unopened 
sterile packaging.  
 
 
Figure 5. Zirconia dental implant, WhiteSky, Bredent®, 4.0x12mm 
 
3.2 Bacterial contamination of dental implants 
 
All microbiological procedures were performed at the laboratory of the Department of Clinical 
and Molecular Microbiology, University Hospital Centre Zagreb. 
A bacterial suspension was prepared from three bacteria: Prevotella intermedia, Aggregatibacter 
actinomycetemcomitans, and Porphyromonas gingivalis.  
The strain of Prevotella intermedia was isolated from a clinical sample at the Clinical Hospital 
Centre in Zagreb. Aggregatibacter actinomycetemcomitans (ATCC
®
 33384) and Porphyromonas 
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gingivalis (ATCC
®
 33277) were purchased from The Leibniz Institute DSMZ – German 
Collection of Microorganisms and Cell Cultures, Germany as dry frozen cultures.  
The bacteria were grown separately in Columbia Agar for 72 hours and then, using thioglycolate 
broth, a bacterial suspension was prepared for each of the bacteria and mixed together in a joint 
suspension. A density of 600 nm equivalent of 1x10
8 
CFU/ml (Colony forming units per mililiter) 
was set by optical densitometer (Densimat, Biomerieux, Marcy l’Etoile, France) (Figure 6). 
 
Figure 6. Optical densitometer, Densimat Biomeraux 
 
 
Every single implant was put in sterile Eppendorf tubes (Eppendorf, Hamburg, Germany) 
containing 300 µl of the prepared bacterial suspension (Figure 7) and incubated under anaerobic 
conditions for 72 hours using GasPak
® 
anaerobic system (Becton, Dickinson and Co, Maryland, 
USA) (Figure 8). The bacterial suspension covered the entire lengths of the implants in the 
Eppendorf tubes.  
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Figure 7. Implants placed in Eppendorf tubes containing bacterial suspension. Implants covered 
in their entire length by the bacterial suspension 
 
 
Figure 8. GasPak® anaerobic system 
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3.3 Antimicrobial protocols 
 
After the incubation period, the implants were taken out of anaerobic chamber conditions and 
randomly divided into four study groups (n=12 implants/group) and two control groups (n=12). 
 
3.3.1 Group 1. LaserHF treatment group (PDT1) 
 
The implants were treated with a diode laser (660 nm, Laser HF
®
, Hager Werken, Duisburg, 
Germany) with 320 µm optical flat fiber tip and a toluidine blue-based dye (155 μg/ml, LaserHF® 
Paro-PDT solution) (Figure 9). The laser parameters are presented in Table 1. 
 
 
Figure 9. Diode laser, Laser HF
®
 (Hager Werken, Duisburg, Germany) 
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Table 1. Treatment parameters of PDT1 
Wavelength: 660nm 
Fiber tip: 320 µm optical  fiber tip 
Power output: 100 mW 
Power density: 124.3 W/cm
2
 
Irradiation Time: 60 seconds 
Distance from the implant: 5mm 
 
 
3.3.2 Group 2. Helbo treatment group (PDT2) 
 
The implants were treated with a diode laser (660 nm, Helbo
®
 Therapielaser, Helbo 
Photodynamic Systems GmbH & Co KG, Grieskirchen, Austria) and a 3D fiber optic tip with a 
spot size of 0.06 cm in diameter (HELBO 3D Pocket Probe, Helbo Photodynamic Systems 
GmbH & Co KG), with phenothiazine chloride dye (10 mg/ml, Helbo
®
 Blue photosensitizer) 
(Figure 10). The laser parameters are presented in Table 2. 
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Figure 10. Diode laser Helbo® (Helbo, Grieskirchen, Austria). 
 
Table 2. Treatment parameters of PDT2 
Wavelength: 660nm 
Fiber tip: 3D pocket probe 
Power output: 100 mW 
Power density: 35.37W/cm
2 
Irradiation Time: 60 seconds 
Distance from the implant: 5mm 
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3.3.3 Group 3. Light-emitting diode treatment group (PDT3) 
 
The implants were treated with LED curing light (Optilight Ld
®
, Gnatus, Brazil). The curing light 
was modified with a red LED light, (660 nm, LZ1-00R205, Ledengin,Inc.
®
, San Jose, USA). A 
toluidine blue solution (Biognost
®
, Zagreb, Croatia) was used as a photosensitive dye. The 
diameter of the tip was 6 mm (Figure 11). The laser parameters are presented in Table 3. 
 
Figure 11. LED lamp (Optilight Ld®, Gnatus, Brazil) 
Table 3. Treatment parameters of PDT3 
Wavelength: 660nm 
Fiber tip:  6mm  LED composite curing tip 
Power output: 200 mW 
Power density: 0.71 W/cm
2 
Irradiation Time: 60 seconds 
Distance from the implant: 5mm 
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3.3.4 Decontamination procedures for PDT1, PDT2 and PDT3 
 
The implants were first coated with the photosensitive dye and left for 60 seconds, and then 
rinsed with sterile saline solution in order to remove the excess of the photosensitive dye. In order 
to standardize the irradiation treatment protocols for all implants, the implants were placed in a 
rotational electric motor (Shenzhen Powerful Electronics, Shajing, China), with a power of 12 V, 
120 mA with a rotating speed of 10 rounds per minute.  
The titanium implants were fixed to the electric motor using an insertion drill (SKY TK Mounter 
long) which was glued to the motor and then the implants were placed on that drill.  
For the zirconia implants, the implant holder from the packaging was used for the same purpose. 
It was glued to the rotational motor and then the implants were placed in the holder in the same 
manner as the titanium implants. The light source was placed approximately 5 mm away from the 
surface of the rotating implant in a static holder and the treatment time was 60 seconds. The 
treatment procedures for titanium and zirconia implants are shown in Figures 12 and 13. 
 
 
 
Figure 12. Titanium implant placed in a rotational motor and treated with PDT1. 
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Figure 13. Zirconia implant placed in a rotational motor and treated with PDT2. 
 
3.3.5 Group 4. Toluidine blue treatment (TB) 
 
The implants were immersed in a photosensitive dye (toluidine blue; Biognost
®
, Zagreb, Croatia) 
solution (1 mg/ml) for 60 seconds and then they were rinsed with sterile saline solution to remove 
the excess dye.  
 
3.3.6 Control Groups 
 
In the negative control group (NC), the implants did not receive any treatment, and after their 
removal from the bacterial suspension, the implants were kept in room conditions for 60 seconds 
before microbiological analysis.  
In the positive control group (PC), the implants were immersed in 0.2% chlorhexidine gluconate 
solution (Curasept ADS
® 
Curaden International AG, Kriens, Switzerland) for 60 seconds (Figure 
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14). After their removal from the chlorhexidine solution, the implants were rinsed with sterile 
saline to remove the remaining solution. 
 
 
 
Figure 14. Titanium dental implant immersed in 0.2% chlorhexidine (PC group). 
 
3.4 Microbiological analysis 
 
Immediately after the treatment procedures, every implant was placed in a 1.5 ml Eppendorf test 
tube containing 500 µl of phosphate buffered saline (PBS) and vortexed for 60 seconds (Vortex, 
Genius 3, IKA, Germany) to remove the remaining bacterial cells from their surfaces (Figure 15). 
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Figure 15. Vortex, Genius 3, IKA, Germany. 
 
From each tube, 100 µl were transferred to 100 µl of Mueller Hinton broth, and a volume of 20 µl 
of PBS was also transferred to a microplate well containing 180 µl of broth creating a 10-fold 
dilution. Ten-fold serial dilution was performed by using 96-well microtiter plates; 30 µl of 
suspension from each well was then inoculated to Brucella agar plates (Figures 16 and 17). 
 
 
Figure 16. 96-well microtiter plate used for ten-fold serial dilution. 
Bleron Azizi   Dissertation 
 
39 
 
 
 
Figure 17. Brucella agar plate with marked dilution prior to inoculation of the suspension. 
The plates were incubated in anaerobic conditions for 72 hours and the colony forming units per 
mililiter (CFU/ml) were counted on Brucella agar plates (Figure 18). Macroscopically distinctive 
colonies were confirmed with MALDI Biotyper (Bruker Daltonics, Germany). 
 
 
  
Figure 18. Brucella agar plates with visible colonies of bacteria. 
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3.5 Scanning electron microscopy analysis 
 
After microbiological analysis, one random implant was chosen from each of the treatment 
groups and one sterile non-treated implant was chosen for scanning electron microscopy (SEM). 
The implants for SEM were stored in paraformaldehyde 2% for 2 hours. Then, the implants were 
dehydrated in increasing concentrations of ethanol (60%, 75% and 95%), for 30 minutes in each 
and were then left for drying all night. The surfaces of the implants were observed using SEM 
(Vega TS5136MM, Tescan, Brno, Czech Republic) (Figure 19). The SEM images were taken at 
1:250 magnifications under high vacuum (HiVac) with a high voltage (HV) of 30kV. All the 
images were taken between the fourth and the fifth thread of the implants.  
 
 
Figure 19. Scanning Electron Microscope (Vega, Brno, Czech Republic). 
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As for the zirconia implants, they are non conducting material and in order to make the samples 
conductive and avoid charging of the sample surface, the implants were coated with gold and 
palladium sputter (SC7620 Mini Sputter Coater, Quorum Technologies Ltd, UK) (Figure 20). 
 
 
 
Figure 20. Gold and palladium sputter for the zirconia implants (SC7620 Mini Sputter Coater, 
Quorum Technologies Ltd, UK). 
 
 
3.6 Statistical analysis 
 
To determine the difference between the groups for each bacterial species separately and for the 
total count of bacteria, the obtained data were compared by analysis of variance test (ANOVA). 
Multiple comparisons between the applied methods were done by Tukey test. The level of 
significance was set at 5%. Due to the large differences in the standard deviations between the 
groups, the data were transformed according to the following equation: 
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L=log10(N+1). 
 
To calculate the bacterial log reduction and the reduction in percentage compared to the NC 
group, the following formulae were used:  
 
1-
T
C
=100 (1-
T
C
)%.                                  log
10
C
T
= log
10
C -log
10
T. 
 
Here, T stands for the Treatment group and C stands for the negative control group (NC).  
All calculations were performed using the statistical package SAS system for Windows (Release 
8.02, SAS Institute Inc., Cary, NC, USA). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. Results 
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4.1 Descriptive statistics 
 
Descriptive statistics for each bacteria separately and the total bacterial count for both titanium 
and zirconia implants are presented in Tables 4-11. They are presented in CFU/ml (colony 
forming units per mililiter) and also transformed in logarithmic form.  
 
Table 4. Titanium implants; Descriptive statistics for A.Actynomycetemcomitans (mean and 
standard deviation) in Cfu/ml and transformed data (mean and standard deviation) in logarithmic 
form. 
Group Mean St. dev Mean (log) St. dev (log) 
PDT1 208,457 (331,464) 3.3 (2.2) 
PDT2 192,427 (570,940) 3.1 (2.0) 
PDT3 60,520,200 (170,844,881) 5.4 (2.3) 
TB 84,338,383 (117,993,238) 6.2 (2.3) 
PC 44,172,684 (87,638,353) 4.7 (2.7) 
NC 121,192,667 (289,930,108) 6.5 (1.7) 
 
 
Table 5. Titanium implants; Descriptive statistics for P. gingivalis (mean and standard deviation) 
in CFU/ml and transformed data (mean and standard deviation) in logarithmic form. 
Group Mean St. dev Mean (log) St. dev (log) 
PDT1 6,643,624 (20,035,962) 3.7 (2.5) 
PDT2 254,624 (588,104) 2.8 (2.4) 
PDT3 28,306,092 (61,302,933) 5.2 (2.2) 
TB 34,253,542 (43,280,627) 6.2 (2.0) 
PC 16,670,794 (31,716,093) 4.7 (2.3) 
NC 328,280,033 (678,053,479) 6.8 (1.9) 
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Table 6. Titanium implants; Descriptive statistics for P. intermedia (mean and standard deviation) 
in CFU/ml and transformed data (mean and standard deviation) in logarithmic form. 
Group Mean St. dev Mean (log) St. dev (log) 
PDT1 6,683,834 (12,299,136) 4.3 (2.4) 
PDT2 16,801,042 (57,693,469) 3.6 (2.4) 
PDT3 158,917,850 (267,478,190) 5.4 (3.1) 
TB 179,250,925 (270,408,827) 6.7 (2.4) 
PC 75,007,679 (121,537,940) 4.9 (2.7) 
NC 342,008,583 (554,467,604) 7.0 (2.2) 
 
 
 
Table 7. Titanium implants; Descriptive statistics for the total number of bacteria (mean and 
standard deviation) in CFU/ml and transformed data (mean and standard deviation) in logarithmic 
form. 
Group Mean St. dev Mean (log) St. dev (log) 
PDT1 13,534,248 (24,854,759) 4.7 (2.3) 
PDT2 17,239,759 (58,193,987) 3.9 (2.3) 
PDT3 247,744,142 (466,066,101) 6.1 (2.5) 
TB 297,842,850 (352,941,629) 7.0 (2.2) 
PC 135,851,158 (202,357,373) 5.4 (2.6) 
NC 791,481,283 (1,496,114,298) 7.4 (1.8) 
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Table 8. Zirconia Implants; Descriptive statistics for A.Actynomycetemcomitans (mean and 
standard deviation) in CFU/ml and transformed data (mean and standard deviation) in logarithmic 
form. 
Group Mean St. dev Mean (log) St. dev (log) 
PDT1 19 (57) 0.4 (0.8) 
PDT2 7 (12) 0.4 (0.6) 
PDT3 61 (107) 0.8 (1.1) 
TB 7,270 (15,323) 2.4 (1.3) 
PC 128 (287) 1.2 (1.0) 
NC 2,858,333 (5,731,009) 5.9 (0.7) 
 
 
 
Table 9. Zirconia Implants; Descriptive statistics for P. gingivalis (mean and standard deviation) 
in CFU/ml and transformed data (mean and standard deviation) in logarithmic form. 
Group Mean St. dev Mean (log) St. dev (log) 
PDT1 19 (57) 0.4 (0.8) 
PDT2 3 (5) 0.3 (0.5) 
PDT3 21 (57) 0.6 (0.7) 
TB 1,908 (5,726) 1.9 (1.1) 
PC 127 (233) 0.9 (1.2) 
NC 6,804,167 (19,961,421) 5.7 (1.0) 
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Table 10. Zirconia Implants; Descriptive statistics for P. intermedia (mean and standard 
deviation) in CFU/ml and transformed data (mean and standard deviation) in logarithmic form. 
Group Mean St. dev Mean (log) St. dev (log) 
PDT1 31 (57) 0.8 (0.9) 
PDT2 10 (17) 0.5 (0.7) 
PDT3 40 (75) 0.8 (0.9) 
TB 2,809 (6,240) 2.3 (1.2) 
PC 736 (1,199) 1.5 (1.5) 
NC 13,321,833 (29,535,046) 5.9 (1.3) 
 
 
 
Table 11. Zirconia Implants; Descriptive statistics for the total number of bacteria (mean and 
standard deviation) in CFU/ml and transformed data (mean and standard deviation) in logarithmic 
form. 
Group Mean St. dev Mean (log) St. dev (log) 
PDT1 69 (169) 0.9 (1.0) 
PDT2 20 (32) 0.7 (0.8) 
PDT3 122 (183) 1.1 (1.2) 
TB 11,987 (24,717) 2.9 (1.2) 
PC 991 (1,472) 1.8 (1.5) 
NC 22,984,333 (37,486,543) 6.7 (0.9) 
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4.2 Results of Multivariate analysis of variance (MANOVA) 
 
To determine the difference among the groups and between the two types of implants, MANOVA 
test was applied. Results of the test are given in Table 12. 
 
Table 12. Results of MANOVA analysis. 
  
A.actynomycete-
mcomitans 
P.  gingivalis P.  intermedia Total 
Wilks'  
lambda 
Factor 
D
F SS p* 
D
F SS p* 
D
F SS p* 
D
F SS p* p 
Implants 1 328.8 
< 
0.001 1 378.7 
< 
0.001 1 403.2 
< 
0.001 1 
419.
5 
< 
0.001 
< 
0.0001 
Group 5 336.2 
< 
0.001 5 337.2 
< 
0.001 5 304.8 
< 
0.001 5 
359.
6 
< 
0.001 
< 
0.0001 
Implants*Gr
oup 5 55.3 0.003 5 50.3 0.005 5 44.8 0.045 5 60.5 0.003 0.0001 
*-p-value for ANOVA test 
 
Wilks's lambda statistic showed that there was a significant difference in the number of bacteria 
between types of implants and between different groups (p<0.0001 for both factors, MANOVA 
test). Interaction between groups and implants type was also significant (p=0.0001, MANOVA 
test). Since all factors and interactions were significant, ANOVA test was applied to the number 
of each bacterium separately and to the total number of bacteria. All ANOVA tests showed that 
two factors and their interaction were significant (Table 12). 
The comparison between titanium and zirconia implants, regardless of the study groups, showed 
that for all three types of bacteria separately, as well as for the total number of bacteria, there was 
a significantly lower number of bacteria on zirconia implants (Table 13). 
Tukey test was applied for the comparison among the study groups regardless of the type of 
implant. Regarding the total number of bacteria, the lowest number of bacteria was found in 
PDT1 and PDT2, followed by PDT3 and PC without significant difference among them. NC 
group had significantly the largest number of bacteria when compared to the other groups (Table 
13). 
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Identical results were obtained for the number of A. actynomycetemcomitans,  P. gingivalis and 
P. intermedia separately (Table 13). 
 
Table 13. Number of bacteria by factors. 
 
A. actynomycetemcomitans P. gingivalis 
Factor N mean st.d. 
 
p* N mean st.d. 
 
p* 
Implants 
          
Zirconia 72 1.9 (2.1) 
 <0.0001 
72 1.6 (2.1) 
 <0.0001 
Titanium 72 4.9 (2.5) 
 
72 4.9 (2.6) 
 
Group 
          
PDT1 24 1.9 (2.2) b 
<0.0001 
24 2.0 (2.5) b 
<0.0001 
PDT2 24 1.8 (2.0) b 24 1.6 (2.1) b 
PDT3 24 3.1 (2.9) ab 24 2.9 (2.8) ab 
TB 24 4.3 (2.7) a 24 4.0 (2.7) a 
PC 24 2.9 (2.7) ab 24 2.8 (2.6) ab 
NC 24 6.2 (1.3) 
 
24 6.2 (1.6) 
 
 
P. intermedia Total 
Factor N mean st.d. 
 
p* N mean st.d. 
 
p* 
Implants 
          
Zirconia 72 2.0 (2.1) 
 <0.0001 
72 2.3 (2.3) 
 <0.0001 
Titanium 72 5.3 (2.7) 
 
72 5.8 (2.5) 
 
Group 
          
PDT1 24 2.6 (2.5) b 
<0.0001 
24 2.8 (2.6) b 
<0.0001 
PDT2 24 2.0 (2.3) b 24 2.3 (2.4) b 
PDT3 24 3.1 (3.2) ab 24 3.6 (3.2) ab 
TB 24 4.5 (2.9) a 24 5.0 (2.7) a 
PC 24 3.2 (2.7) ab 24 3.6 (2.7) ab 
NC 24 6.4 (1.8) 
 
24 7.1 (1.5) 
 
 
The total number of bacteria for the different groups and two implants type are shown in Figure 
21. The difference between zirconia implants instead of titanium implants is not the same for all 
groups. The smallest difference between them in the number of bacteria is for the control group. 
The impact is almost the same for PDT1, PDT2, PC and TB, while the largest difference between 
titanium and zirconia implants were in the PDT3 group. The results for each of the bacteria 
separately are shown in Figures 22-24. 
 
Bleron Azizi   Dissertation 
 
50 
 
 
Figure 21. Comparison of total number of bacteria by type of implant and group. 
 
Figure 22. Comparison of the number of A. actinymycetemcomitans by type of implant and 
group. 
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Figure 23. Comparison of the number of P. gingivalis by type of implant and group. 
 
Figure 24. Comparison of the number of P. intermedia by type of implant and group. 
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4.2.1.1 Titanium implants 
 
For the titanium implants, the results showed that there were statistically significant differences 
among the groups for each bacterial species separately and also for the total number of bacteria 
(p=0.0022). These data are presented in logarithmic form in Table 14. The bacterial reduction 
compared to the negative control group, expressed in percentage and log reduction, is shown in 
Table 15. The largest bacterial reduction in term of the total count of bacteria was recorded in the 
PDT1 (98.3%) and PDT2 (97.8%) groups. These two groups were significantly superior 
compared to NC (p<0.05). PDT3 group caused a 68.7% (Table 15) bacterial reduction and did not 
show significant differences when compared to NC (Table 14).  
 
Table 14. Results of ANOVA and Tukey's post hoc test for the Titanium implants 
 
A. actynomycetemcomitans P.  gingivalis 
Wilks'  
lambda 
Group N mean st.d. 
 
p* N mean st.d. 
 
p* p 
PDT1 12 3.3 2.2 b 0.0006 12 3.7 2.5 bc 0.0003 0.0026 
PDT2 12 3.1 2.0 b 
 
12 2.8 2.4 c 
  
PDT3 12 5.4 2.3 ab 
 
12 5.2 2.2 abc 
  
TB 12 6.2 2.3 a 
 
12 6.2 2.0 ab 
  
PC 12 4.7 2.7 ab 
 
12 4.7 2.3 abc 
  
NC 12 6.5 1.7 a 
 
12 6.8 1.9 a 
  
 
P. intermedia Total 
Wilks'  
lambda 
Group N mean st.d. 
 
p* N mean st.d. 
 
p* p 
PDT1 12 4.3 2.4 ab 0.0096 12 4.7 2.3 bc 0.0022 0.0026 
PDT2 12 3.6 2.4 b 
 
12 3.9 2.3 c 
 
PDT3 12 5.4 3.1 ab 
 
12 6.1 2.5 abc 
 
TB 12 6.7 2.4 a 
 
12 7.0 2.2 ab 
  
PC 12 4.9 2.7 ab 
 
12 5.4 2.6 abc 
  
NC 12 7.0 2.2 a 
 
12 7.4 1.8 a 
  
* - p-value for ANOVA test 
abc - result of post-hoc comparison (Tukey test).  Means with the same letter are not significantly 
different. 
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The PDT1 and PDT2 groups also showed the largest bacterial reduction when compared to each 
of the bacteria separately. Compared to the NC, the PDT1 group was significantly more effective 
in the eradication of A. actinomycetemcomitans and P. gingivalis (p<0.05), however without 
significant difference in the eradication of P. intermedia. The PDT2 group was significantly more 
effective in the eradication of each of the bacteria when compared to the NC group (p<0.05). 
The toluidine blue group (TB) was the least effective compared to  other study groups with only 
62.4% bacterial reduction; moreover, it did not differ significantly compared to the NC in terms 
of the total number of bacteria or for each of the bacteria separately. 
 
Table 15. Bacterial reduction compared to the NC group in percentage and log reduction for the 
titanium implants.  
  A.actynomycetemcomitans P. gingivalis 
Group Mean (St.d.) 
Reduction Log 
Mean (St.d.) 
Reduction Log 
% reduction % reduction 
PDT1 2.08E+05 3.31E+05 99.8 2.9 6.64E+06 2.00E+07 98 1.5 
PDT2 1.92E+05 5.71E+05 99.8 2.7 2.55E+05 5.88E+05 99.9 3.1 
PDT3 6.05E+07 1.71E+08 50.1 0.2 2.83E+07 6.13E+07 91.4 1 
TB 8.43E+07 1.18E+08 30.4 0.4 3.43E+07 4.33E+07 89.6 1.2 
PC 4.42E+07 8.76E+07 63.6 0.5 1.67E+07 3.17E+07 94.9 1.3 
NC 1.21E+08 2.90E+08     3.28E+08 6.78E+08     
  P. intermedia Total 
Group Mean (St.d.) 
Reduction Log 
Mean (St.d.) 
Reduction Log 
% reduction % reduction 
PDT1 6.68E+06 1.23E+07 98 1.7 1.35E+07 2.49E+07 98.3 1.8 
PDT2 1.68E+07 5.77E+07 95.1 1 1.72E+07 5.82E+07 97.8 1.4 
PDT3 1.59E+08 2.67E+08 53.5 0.3 2.48E+08 4.66E+08 68.7 0.5 
TB 1.79E+08 2.70E+08 47.6 0.3 2.98E+08 3.53E+08 62.4 0.6 
PC 7.50E+07 1.22E+08 78.1 0.7 1.36E+08 2.02E+08 82.8 0.9 
NC 3.42E+08 5.54E+08     7.91E+08 1.50E+09     
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4.2.1.2 Zirconia implants 
 
For the zirconia implants, the results showed statistically significant differences among the 
groups for each bacterial species separately and also for the total number of bacteria (p<0.0001). 
The bacterial reduction results showed a huge bacterial reduction for every group compared to the 
NC. The results are presented in Table 16 and the bacterial reduction in percentage is presented in 
Table 17.  
 
Table 16. Results of ANOVA and Tukey's post hoc test for the Zirconia implants 
 
A. actynomycetemcomitans P.  gingivalis 
Wilks'  
lambda 
Group N mean st.d. 
 
p* N mean st.d. 
 
p* p 
PDT1 12 0.4 0.8 a 0.0001 12 0.4 0.8 b 0.0001 0.0001 
PDT2 12 0.4 0.6 a 
 
12 0.3 0.5 b 
  
PDT3 12 0.8 1.1 a 
 
12 0.6 0.7 b 
  
TB 12 2.4 1.3 
  
12 1.9 1.1 a 
  
PC 12 1.2 1.0 a 
 
12 0.9 1.2 ab 
  
NC 12 5.9 0.7 
  
12 5.7 1.0 
   
 
P. intermedia Total 
Wilks'  
lambda 
Group N mean st.d. 
 
p* N mean st.d. 
 
p* p 
PDT1 12 0.8 0.9 b 0.0001 12 0.9 1.0 b 0.0001 0.0001 
PDT2 12 0.5 0.7 b 
 
12 0.7 0.8 b 
 
PDT3 12 0.8 0.9 b 
 
12 1.1 1.2 b 
 
TB 12 2.3 1.2 a 
 
12 2.9 1.2 a 
  
PC 12 1.5 1.5 ab 
 
12 1.8 1.5 ab 
  
NC 12 5.9 1.3 
  
12 6.7 0.9 
   
* - p-value for ANOVA test 
abc - result of post-hoc comparison (Tukey test).  Means with the same letter are not significantly 
different. 
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In terms of the total count of bacteria every group had a statistically significant difference when 
compared to the NC (p<0.05). The bacterial reduction was more than 99% in each group. The 
PDT1, PDT2 and PDT3 had the largest bacterial reduction for each bacterium separately, as well 
as for the total count of bacteria. In addition to the difference to the NC group, these three groups 
also had statistically significant differences compared to the TB group (p<0.05). Between them, 
however, the differences in bacterial reduction were small and there was no statistically 
significant difference neither for each of the bacteria separately nor for the total count of bacteria 
(p>0.05).  
  
Table 17. Bacterial reduction compared to the NC group in percentage and log reduction for the 
titanium implants. 
  A. actynomycetemcomitans P. Gingivalis 
Group Mean (St.d.) 
Reduction Log 
Mean (St.d.) 
Reduction Log 
% reduction % reduction 
PDT1 1.92E+01 5.73E+01 99.9 5 1.92E+01 5.73E+01 99.9 5.5 
PDT2 6.67E+00 1.23E+01 99.9 5.7 3.33E+00 4.92E+00 99.9 6.6 
PDT3 6.08E+01 1.07E+02 99.9 4.7 2.08E+01 5.66E+01 99.9 5.5 
TB 7.27E+03 1.53E+04 99.7 2.6 1.91E+03 5.73E+03 99.9 3.5 
PC 1.28E+02 2.87E+02 99.9 4.3 1.27E+02 2.33E+02 99.9 4.9 
NC 2.86E+06 5.73E+06     6.80E+06 2.00E+07     
  P. Intermedia Total 
Group Mean (St.d.) 
Reduction Log 
Mean (St.d.) 
Reduction Log 
% 
reductio
n 
% reduction 
PDT1 3.08E+01 5.66E+01 99.9 5.7 6.92E+01 1.69E+02 99.9 5.3 
PDT2 1.00E+01 1.65E+01 99.9 6.3 2.00E+01 3.19E+01 99.9 6.1 
PDT3 4.00E+01 7.53E+01 99.9 5.6 1.22E+02 1.83E+02 99.9 5.3 
TB 2.81E+03 6.24E+03 99.9 3.7 1.20E+04 2.47E+04 99.8 3.2 
PC 7.36E+02 1.20E+03 99.9 4.4 9.91E+02 1.47E+03 99.9 4.4 
NC 1.33E+07 2.95E+07     2.30E+07 3.75E+07     
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The TB group had the lowest bacterial reduction for every bacterium separately and also for the 
total bacterial count. Moreover, the TB group did not have a statistically significant difference for 
A. actinomycetemcomitans compared to the NC (p>0.05). The PC group had lower bacterial 
reduction compared to PDT1, PDT2 and PDT3, but without statistically significant differences 
among them. It also did not differ significantly compared to the TB in terms of the total bacterial 
count, P. gingivalis and P. intermedia. It had a significant difference compared to the TB only for 
A. actinomycetemcomitans. 
 
4.3 Scanning Electron Microscope analysis 
 
The SEM images obtained from the PDT1, PDT2, and PDT3 groups visually did not show any 
surface alterations, cracks, or damage when compared to the images obtained for the sterile 
implants, and their surface appeared to be very similar to the surface of the sterile implant. The 
same results were obtained for both titanium and zirconia implants. The obtained images are 
shown in 1:250 magnification in Figures 25-32. 
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Figure 25. Sterile titanium implant; magnification 1:250. 
 
Figure 26. Titanium implant treated with PDT1; magnification 1:250. 
Bleron Azizi   Dissertation 
 
58 
 
 
Figure 27. Titanium implant treated with PDT2; magnification 1:250. 
 
Figure 28. Titanium implant treated with PDT3; magnification 1:250. 
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Figure 29. Sterile zirconia implant; magnification 1:250. 
 
Figure 30. Zirconia implant treated with PDT1; magnification 1:250. 
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Figure 31. Zirconia implant treated with PDT2; magnification 1:250. 
 
Figure 32. Zirconia implant treated with PDT3; magnification 1:250. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5. Discussion 
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Peri-implantitis is considered to be one of the main causes of implant failure. There are numerous 
studies that report various prevalence rates of peri-implant disease due to different reporting 
methods and study characteristics (173–176). Van Velsen et al. (173) reported a 7% rate of peri-
implantitis in their 10-year prospective cohort study. Meijer et al. (174) in their study reported 
that 29.7% of patients after 10 years were affected by peri-implantitis. According to Atieh et al. 
(175), in their meta-analysis peri-implantitis affects 18.8% of patients and 9.6% of the implants. 
Fardal et al. (176) report an even higher number of patients affected with peri-implantitis. In their 
retrospective study they conclude that patients initially treated for periodontitis have a prevalence 
of peri-implantitis of 53.5% at the patient level and 31.1% at the implant level.  
 The lack of a clear protocol for treating peri-implantitis has increased the focus of the scientific 
community towards the use of photodynamic therapy as a treatment option or an adjuvant 
treatment for peri-implantitis in the recent years (11,177,178). 
Photodynamic therapy is a promising alternative when treating periodontal diseases and peri- 
implant diseases. In the present study, the effect of photodynamic therapy was evaluated on 
artificially contaminated dental implants under in-vitro conditions. The contamination of the 
implants was performed in order to reproduce the adhesion stage of biofilm formation. A similar 
methodology has been used in many other studies with in vitro contamination and 
decontamination of titanium implants (11,177,179). 
 The main focus of the study was to determine if photodynamic therapy is efficient as compared 
to the negative control group (NC) and to the conventional disinfection with chlorhexidine 
solution (PC). Furthermore, the focus was to investigate if different types of devices and 
photosensitizers affect the results of aPDT and whether different bacteria react differently to 
aPDT depending on the photosensitizer and the light source.  
When decontaminating the implant surfaces it is of utmost importance not to cause damage to the 
implant surface which might interfere with the re-osseointegration of the implant (9,180). For this 
purpose, in this study the implants were examined under scanning electron microscope in order to 
evaluate if aPDT causes any surface alterations.  
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5.1 The effect of aPDT on titanium implants 
 
Recent advances in the production of titanium dental implants aim to achieve a faster 
osseointegration through roughening the implant surfaces. The challenges of decontaminating 
rough titanium surfaces lies in the fact that the surface roughness in addition to better and faster 
osseointegration,  also  enables the bacteria to adhere more to the surface, which makes it difficult 
for the conventional treatment methods to successfully eliminate the bacteria from the implant 
surface (160). 
The obtained results from the present study showed that PDT1 and PDT2 groups caused great 
bacterial reduction when compared to the NC group (98.3% and 97.8%). The NC group, as 
expected, had the greatest bacterial count among all other groups. Both PDT1 and PDT2 groups 
were a combination of a diode laser as a light source and a photosensitizer.   
The results of this study are in accordance with other in vitro, in vivo and clinical studies 
(9,11,177,181,182).  In a similar in vitro study, Marotti et al. (11) showed that aPDT using a 
GaAlAs low-level diode laser in combination with methylene blue dye is effective against the 
bacteria present in peri-implantitis. The irradiation time did not influence the results, as both 
subgroups of aPDT with respective irradiation time of 3 minutes and 5 minutes had similar 
results without significant differences between them. The effect of aPDT was comparable to the 
positive control with 0.12% chlorhexidine solution. Similar results were obtained in our study 
when PDT1 and PDT2 were compared to the PC group, even though the concentration of 
chlorhexidine used in our study was 0.2%.  
In another study Haas et al. (9) showed that short term exposure (60 seconds) to light and 
photosensitizer can effectively kill A. actinomycetemcomitans, P.gingivalis and  P.intermedia. In 
their study they used a 905nm light source with a power output of 7.3mW and toluidine blue as a 
photosensitizer. Even though  we obtained similar results in the present study, the light source 
used was between 600-700nm and a higher power output was used.  
In an in vivo study, Shibli et al. (181) evaluated the effect of GaAIAs low-level diode laser with a 
wavelength of 685nm for a duration of 80 seconds in combination with toluidine blue on dogs. 
They concluded that this combination shows a significant reduction and in some cases the 
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elimination of the pathogenic bacteria associated with peri-implantitis. In another study by Shibli 
et al. (182), guided bone regeneration and aPDT was used to treat ligature-induced peri-
implantitis in dogs. According to their results, there was up to 41.19 % better re-osseointegration 
in the test groups compared to the control group, which suggests a very good effect of aPDT. 
In human studies, the combination of a diode laser with a wavelength of 690 nm with toluidine 
blue O for 60 seconds has been shown to be effective against P.gingivalis, P. intermedia and A. 
actinomycetemcomitans in decreasing their count by 92%. However, the complete elimination of 
the bacteria was not demonstrated (177).  
In the present study the effect of aPDT was also evaluated on each bacterium separately. With 
regard to A.actinomycetemcomitans and P. gingivalis, the results were almost identical to the 
total bacterial count with PDT1 and PDT2, both being significantly different compared to the NC. 
However, regarding the effect on the bacterial count of P.intermedia, only PDT2 was 
significantly different when compared to the NC.  PDT1 and PDT2 had very similar effect 
without significant difference between them.   
PDT3 was the least effective treatment group among the PDT groups and did not differ 
significantly compared to the NC or to the PC groups, having even lower bacterial reduction than 
the PC group regarding the total number of bacteria. The same results were obtained for the 
number of each bacterium separately.  However, it must be pointed out that in contrast to PDT1 
and PDT2, the implants belonging to the PDT3 group were treated using a modified dental LED 
curing light and not with a laser light source. This was done in order to test the LED light as an 
alternative light source to lasers.  
Many recent studies have tested the efficacy of LED lights as a photodynamic light source, yet 
only a few of them have been conducted on implant surfaces. The results of these studies vary 
and are dependent on the study design, power output, irradiation time, and the photosensitizer 
used.  Cho et al. (30) in their study tested the efficacy of a green LED light with the power output 
of 150 mW/cm2 in combination with erythrosine against A.actinomycetemcomitans. According to 
their results, this combination is very effective in reducing the bacteria attached to different 
titanium surfaces, with the reduction reaching up to 92.4% for a 60 second irradiation of the 
implant surface. The irradiation was done on titanium discs on only one surface providing a 
uniform irradiation of the surface. On the other hand, in the present study the light was applied in 
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a rotating implant in order to copy as much as possible the clinical conditions of applying the 
light source around the dental implant. This might be the reason why there is a difference in the 
efficacy of aPDT with a LED light source with their study, even though the power output of the 
LED device in the present study was 200mW and a 60 second irradiation time was also used.  
In another study, Nielsen HK et al. (43) concluded that the combination of toluidine/red light has 
an excellent antimicrobial effect compared to riboflavin/blue light. Similarly, Umeda M et al. 
(183) reported a good bactericidal effect when using a light emitting diode in combination with 
methylene blue or toluidine blue.  
There are also studies that question the effectiveness of using a LED light for aPDT treatment. De 
Angelis et al. (184) in their clinical study treated 40 patients with mechanical debridement by 
hand, ultrasonic or piezoelectric scalers in combination with a LED light source and 40 patients 
with the same protocol without aPDT. According to their results, after 4 months there was no 
significant difference for any of the clinical parameters, such as pocket depth reduction, bleeding 
on probing (BOP) and clinical attachment levels (CAL) between the groups.  
In the present study, our results showed a reduction of only 68.7% in the total count of bacteria. 
Regarding the number of bacteria separately, the efficacy of the PDT3 ranged from 50.1% 
reduction of A.actinomycetemcomitans to 91.4% reduction of P.gingivalis.  However, statistically 
none of these results was significantly different when compared to the NC.  
We assume that the difference in results between PDT3 and the other two study groups (PDT1 
and PDT2) might be due to the differences in power density. Power density is dependent on the 
power output of the device and the light beam diameter. Since the device used for this research 
was a LED curing light and the light beam diameter was larger than that in PDT1 and PDT2, it 
might be the reason why PDT3 was less effective than PDT1and PDT2. 
Another goal of the present study was to evaluate if different photosensitizers react differently 
with the bacteria used in our study. The most common photosensitizers used for aPDT treatments 
are phenothiazine derivatives. They are also the most effective photosensitizers for eradicating 
oral microorganisms (43). However ,comparing photosensitizers in in vitro conditions is very 
difficult due to the differences in absorption by the photosensitizer and bacteria (10). Moreover, 
some bacteria have the capability of producing endogenous photosensitizers (f.e. Porphyromonas 
gingivalis), a property that further proves the difficulty in comparing photosensitizers in in vitro 
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conditions (185). In the present study we did not find any differences between the groups (PDT1 
and PDT2) that were treated by using different photosensitizers (toluidine blue and phenothiazine 
chloride) in combination with a light source regarding the total bacterial count.  
The use of only diode laser light without the application of photosensitizer has already been 
shown  to be less effective compared to the effect of aPDT (11). In the present study, the use of a 
photosensitizer without the application of a light source (TB group) was evaluated. Based on the 
obtained results, it turned out to be the least effective study group in the present study. There was 
no significant difference between this group and the negative control group, in terms of the total 
bacterial count or in terms of each bacterial species, separately. As in many other studies, this 
further proves that in order to have an effective photodynamic therapy there must be an 
interaction between the light source and the photosensitizer. The use of the photosensitizer or 
light alone are not effective and are not recommended as a treatment option (21, 28, 29).  
 
5.2 The effect of aPDT on zirconia implants 
 
There are many studies that evaluate the effect of aPDT in vitro on titanium implant surfaces, 
animal studies and clinical studies. However, to the best of our knowledge, there are no published 
studies  evaluating the antimicrobial effect of aPDT on zirconia implant surfaces.  
In the present study the results showed that, even though there are differences among the study 
groups, they all had significantly lower bacterial counts compared to NC. This huge difference 
when compared to the NC group might suggest that the bacteria were not strongly attached to the 
implant surface after 72h of incubation. According to other studies, the affinity of bacteria to 
attach to zirconia is significantly lower than titanium surfaces due to their surface properties, such 
as surface roughness and surface free energy (146,186). Scarano et al. (146) in their study placed 
titanium and zirconium oxide discs in the mouths of 10 patients for 24h in order to evaluate the 
adhesion of bacteria in both surfaces. According to their results, zirconium oxide surfaces showed  
significantly less bacteria compared to titanium discs. Al-Radha et al. (186) in their study showed 
similar results. The zirconia material and titanium blasted with zirconia surface showed superior 
effect to titanium material in reducing the adhesion of bacteria, especially after coating with 
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saliva pellicle. In addition to the weak attachment of bacteria on the implant surface, it could be 
assumed that the rinsing of the photosensitizer might have caused an additional detachment of 
bacteria from the implant surface.   
When comparing the study groups among themselves as expected, the most effective were PDT1, 
PDT2 and PDT3. In addition to NC, they differed significantly from the TB group also. When 
compared to PC, even though they had lower bacterial counts, there was no difference among 
them.  It is worth noting that the results obtained from the PDT3 group are comparable to PDT1 
and PDT2, which can suggest that with alternative light sources, such as light-emitting diodes, an 
effective antibacterial effect could be achieved. There are conflicting results regarding the 
antimicrobial effect of using light-emitting-diode as a light source. There are studies that report 
good results after the use of LED lights as a light source (43,183), however there are also studies 
that report that the effect of using LED light for photodynamic therapy does not significantly 
improve  the treatment outcomes (184). However, it is difficult to compare our results with any of 
these studies due to the differences in the study protocol and due to the lack of studies conducted 
on zirconia implant surfaces.    
Similarly, with regard to titanium implants, in terms of the use of different photosensitizers 
among PDT1, PDT2 and PDT3, in our study we could not find any differences as it was 
expected.  
In contrast to the results obtained for the titanium implants, every group in the zirconia implants 
had a lower number of bacteria. This was expected, as in many studies the zirconia implants are 
shown to attract less bacteria to their surface due to surface roughness and surface free energy. 
The largest difference between titanium and zirconia implants was seen in the PDT3 group which 
was very effective for the zirconia implants. Mellinghoff (187) in his review of literature on peri-
implant soft tissues concluded that zirconia implants and abutments provide a very good soft 
tissue interface and irritation free attachment. Reduced plaque adhesion, better healing response 
and less inflammatory infiltrate around zirconia implants when compared to titanium are reported 
in many in vitro and in vivo studies (146,147,188). 
Similarly to the results obtained for the titanium implants, there were no significant differences 
among different photosensitizers used when aPDT was applied on zirconia implants.  
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The least effective among the study groups was the TB group. A similar result was also obtained 
for the titanium implants in the present study. 
In regard to the effect of aPDT on zirconia surfaces, further in vitro and clinical studies are 
needed, especially on the potential efficacy of LED light as a light source for aPDT treatment. 
 
5.3 The effect of aPDT on implant surfaces 
 
In addition to the antimicrobial effect of PDT, the aim of the present study was to examine if PDT 
causes physical alterations on implant surfaces. In the present study the use of two different diode 
lasers and one LED light was evaluated and compared to sterile and unopened (in original 
package), titanium and zirconia implants under scanning electron microscope.  
Laser decontamination of implant surfaces has been shown to be effective in many studies. 
However, it was shown that some lasers  cause damage to the implant surface. Kreisler et al. 
(169) in their study concluded that Nd:YAG and Ho:YAG lasers  significantly damage  the 
surfaces studied at any power settings which makes them unsuitable for the decontamination of 
implant surfaces. Er:YAG  and CO2  lasers damage the implant surfaces at specific settings and 
should be used at a limited power output. Miranda et al. (189) evaluated the effect of 
Er,Cr:YSGG (Eribium, Cromium: yttrium-scandium-gallium-garnet) laser with 1.5 W/20 Hz, air-
water cooling proportion of 80 %/25 %, on zirconia and titanium implants. They concluded that 
the application of Er,Cr:YSGG alters the surface roughness of both zirconia and titanium implant 
surfaces.   
In contrast, the use of diode lasers in many studies has been shown to be safe. Castro et al. (190) 
in their study evaluated whether 980-nm diode laser irradiation causes damage on implant 
surfaces. They reported that the use of this laser does not damage titanium surfaces, and seems to 
be safe irrespective of power output for use on titanium surfaces. Similar results were reported in 
a study conducted by Romanos et al. (191). According to their results, the use of diode laser with 
a wavelength of 980nm and power settings of 5.0, 10.0, and 15.0 W respectively,  in continous 
mode does not cause any damage to titanium plasma-sprayed (TPS), and hydroxyapatite (HA) 
coated implant surfaces. 
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In the present study we did not observe any structural changes on the implant surfaces.  The use 
of two types of diode lasers with 100mW power for 60 seconds, and the use of LED lamp with 
200mW power for 60 seconds, did not cause visible damage  on either titanium or zirconia at a 
magnification of 1:250. 
Our findings are in accordance with a previous study conducted by Haas R. et al. (9), in which 
they examined the  titanium implant surfaces after the treatment with aPDT and compared their 
findings with sterile implants. They reported that aPDT is a  safe method that does not cause any 
surface alterations on titanium surface. 
 To the best of our knowledge, the present study is the first of its kind regarding the evaluation of 
the different types of aPDT on zirconia implant surfaces. This further proves that PDT can be 
safely used for the decontamination of implant surfaces without concerns regarding potential 
damage to the implant surfaces both on titanium and zirconia implant surfaces. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6. Conclusion 
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Considering the limitations of this in vitro study on the efficacy of different types of 
photodynamic therapy and its effect on implant surfaces, the following conclusions can be drawn: 
 
1. Antimicrobial photodynamic therapy using diode lasers (PDT1 and PDT2) significantly 
decreases the bacterial count when compared to negative control on titanium implants. 
 
2. The effect of antimicrobial photodynamic therapy using diode lasers as a light source (PDT1 
and PDT2) is not significantly different from conventional decontamination with 0.2% 
chlorhexidine solution on titanium implants.    
 
3. Antimicrobial photodynamic therapy using light-emitting diode as a light source (PDT3) is the 
least effective method of decontamination among the three aPDT groups without significant 
difference to the NC for titanium implants.  
 
4. The use of  toluidine blue photosensitizer only without the application of light is the least 
effective method of decontamination for titanium implants.  
 
5. All the study groups significantly lowered the bacterial count on zirconia implants compared to 
the NC group. 
 
6. Antimicrobial photodynamic therapy using diode lasers (PDT1 and PDT2) and light emitting 
diode (PDT3) is effective on zirconia implants, significantly reducing the bacterial count when 
compared to the  NC and TB groups.  
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7.  The effect of antimicrobial photodynamic therapy (PDT1, PDT2 and PDT3) on zirconia 
implants is comparable to conventional decontamination with 0.2% chlorhexidine without 
significant differences among these groups.  
 
8. There was no surface damage or alteration either on titanium or zirconia implants after using 
antimicrobial photodynamic therapy.  
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